



\_\_\_\_\_, hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on June 29, 2007.

Frank C. Eisenschek

Frank C. Eisenschek, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group  
Patent Application  
Docket No. ARS-127  
Serial No. 10/576,509

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Phillippe Chatellard, Markus Imhof  
Serial No. : 10/576,509  
Filed : April 19, 2006  
For : Minimal DNA Sequence Acting as a Chromatin Insulator and its Use in Protein Expression

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.


It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

2

Serial No. 10/576,509  
Docket No. ARS-127

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known**

Application Number	10/576,509
Filing Date	April 19, 2006
First Named Inventor	Philippe Chatellard
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-127

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BURGESS-BEUSSE, B. <i>et al.</i> "The Insulation of Genes From External Enhancers and Silencing Chromatin", <i>PNAS</i> , December 10, 2002, pp. 16433-16437, Vol. 99, Suppl. 4.	
	R2	CHUNG, J. H. <i>et al.</i> "A 5' Element of the Chicken $\beta$ -Globin Domain Serves as an Insulator in Human Erythroid Cells and Protects Against Position Effect in <i>Drosophila</i> ", <i>Cell</i> , August 13, 1993, pp. 505-514, Vol. 74.	
	R3	CIANA, P. <i>et al.</i> "Engineering of a Mouse for the <i>in Vivo</i> Profiling of Estrogen Receptor Activity", <i>Molecular Endocrinology</i> , 2001, pp. 1104-1113, Vol. 15, No. 7.	
	R4	SUN, F.-L. <i>et al.</i> "Putting Boundaries on Silence", <i>Cell</i> , November 24, 1999, pp. 459-462, Vol. 99.	
	R5	BELL, A. C. <i>et al.</i> "Stopped at the Border: Boundaries and Insulators", <i>Current Opinion in Genetics &amp; Development</i> , 1999, pp. 191-198, Vol. 9.	
	R6	RECILLAS-TARGA, F. <i>et al.</i> "Positional Enhancer-Blocking Activity of the Chicken $\beta$ -Globin Insulator in Transiently Transfected Cells", <i>PNAS</i> , December 7, 1999, pp. 14354-14359, Vol. 96, No. 25.	
	R7	IZUMI, M. <i>et al.</i> "Homogeneous Tetracycline-Regulatable Gene Expression in Mammalian Fibroblasts", <i>Journal of Cellular Biochemistry</i> , 1999, pp. 280-289, Vol. 76.	
	R8	DE WET, J. R. <i>et al.</i> "Cloning of Firefly Luciferase cDNA and the Expression of Active Luciferase in <i>Escherichia coli</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , December 1985, pp. 7870-7873, Vol. 82.	
	R9	WOOD, K. V. <i>et al.</i> "Synthesis of Active Firefly Luciferase by <i>in Vitro</i> Translation of RNA Obtained From Adult Lanterns", <i>Biochemical and Biophysical Research Communications</i> , October 30, 1984, pp. 592-596, Vol. 124, No. 2.	
	R10	BLACKWOOD, E. M. <i>et al.</i> "Going the Distance: A Current View of Enhancer Action", <i>Science</i> , July 3, 1998, pp. 60-63, Vol. 281.	
	R11	LI, Q. <i>et al.</i> "Locus Control Regions Coming of Age at a Decade Plus", <i>TIG</i> , October 1999, pp. 403-408, Vol. 15, No. 10.	
	R12	MAZUMDER, B. <i>et al.</i> "Translational Control by the 3'-UTR: The Ends Specify the Means", <i>Trends in Biochemical Sciences</i> , February 2003, pp. 91-98, Vol. 28, No. 2.	
	R13	MOUNTFORD, P. S. <i>et al.</i> "Internal Ribosome Entry Sites and Dicistronic RNAs in Mammalian Transgenesis", <i>TIG</i> , May 1995, pp. 179-184, Vol. 11, No. 5.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Call 1-800-PTO-9199 (1-800-786-9199) for a list of offices.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMK/**

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/576,509
Filing Date	April 19, 2006
First Named Inventor	Philippe Chatellard
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARS-127

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R14	SCHÜMPERLI, D. et al. "Efficient Expression of <i>Escherichia coli</i> Galactokinase Gene in Mammalian Cells", <i>Proc. Natl. Acad. Sci. USA</i> , January 1982, pp. 257-261, Vol. 79.	
	R15	ZHU, W.-Y. et al. "The Rate of Folate Receptor Alpha (FRα) Synthesis in Folate Depleted CHL Cells is Regulated by a Translational Mechanism Sensitive to Media Folate Levels, While Stable Overexpression of its mRNA is Mediated by Gene Amplification and an Increase in Transcript Half-Life", <i>Journal of Cellular Biochemistry</i> , 2001, pp. 205-219, Vol. 81.	
	R16	ASSARAF, Y. G. et al. "Characterization of the Coexisting Multiple Mechanisms of Methotrexate Resistance in Mouse 3T6 R50 Fibroblasts", <i>The Journal of Biological Chemistry</i> , March 25, 1992, pp. 5776-5784, Vol. 267, No. 9.	
	R17	ABBATE, J. et al. "Bifunctional Protein Conferring Enhanced Green Fluorescence and Puromycin Resistance", <i>BioTechniques</i> , August 2001, pp. 336-340, Vol. 31, No. 2.	
	R18	SHOTWELL, M. A. et al. "Regulation of Amino Acid Transport System L in Chinese Hamster Ovary Cells", <i>The Journal of Biological Chemistry</i> , March 25, 1982, pp. 2974-2980, Vol. 257, No. 6.	
	R19		
	R20		
	R21		
	R22		
	R23		
	R24		
	R25		

Examiner Signature	/Robert Kelly/ (06/16/2008)	Date Considered	/Robert Kelly/ (06/16/2008)
--------------------	-----------------------------	-----------------	-----------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMK/

J:\ARS\127\PTO-Misc\IDS supp form doc\DNB\gyl